Name | Number of supported studies | Average coverage | |
---|---|---|---|
type II pneumocyte | 3 studies | 20% ± 2% |
Insufficient scRNA-seq data for expression of SLC46A2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 70% | 361.09 | 406 / 578 | 44% | 3.28 | 505 / 1155 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.19 | 1 / 1 |
skin | 71% | 1185.57 | 1287 / 1809 | 6% | 0.19 | 27 / 472 |
peripheral blood | 73% | 180.45 | 674 / 929 | 0% | 0 | 0 / 0 |
bladder | 48% | 244.05 | 10 / 21 | 19% | 1.14 | 96 / 504 |
spleen | 64% | 59.53 | 155 / 241 | 0% | 0 | 0 / 0 |
esophagus | 27% | 33.14 | 391 / 1445 | 8% | 0.12 | 14 / 183 |
brain | 16% | 12.89 | 424 / 2642 | 1% | 0.01 | 4 / 705 |
uterus | 8% | 16.28 | 14 / 170 | 8% | 0.33 | 35 / 459 |
ovary | 1% | 0.87 | 2 / 180 | 13% | 0.24 | 55 / 430 |
thymus | 0% | 0 | 0 / 653 | 14% | 7.45 | 84 / 605 |
blood vessel | 11% | 10.10 | 148 / 1335 | 0% | 0 | 0 / 0 |
breast | 2% | 0.71 | 7 / 459 | 8% | 0.16 | 90 / 1118 |
prostate | 6% | 4.67 | 14 / 245 | 1% | 0.05 | 6 / 502 |
adipose | 5% | 3.82 | 65 / 1204 | 0% | 0 | 0 / 0 |
liver | 1% | 0.49 | 2 / 226 | 4% | 0.18 | 15 / 406 |
pancreas | 1% | 0.46 | 2 / 328 | 2% | 0.08 | 4 / 178 |
kidney | 0% | 0 | 0 / 89 | 3% | 0.07 | 25 / 901 |
intestine | 0% | 0.20 | 3 / 966 | 1% | 0.03 | 6 / 527 |
stomach | 0% | 0 | 0 / 359 | 1% | 0.02 | 4 / 286 |
adrenal gland | 0% | 0 | 0 / 258 | 0% | 0.00 | 1 / 230 |
heart | 0% | 0.11 | 2 / 861 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.42 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
GO_0043029 | Biological process | T cell homeostasis |
GO_0070233 | Biological process | negative regulation of T cell apoptotic process |
GO_0045580 | Biological process | regulation of T cell differentiation |
GO_0048538 | Biological process | thymus development |
GO_0140361 | Biological process | cyclic-GMP-AMP transmembrane import across plasma membrane |
GO_0055085 | Biological process | transmembrane transport |
GO_0045087 | Biological process | innate immune response |
GO_0070430 | Biological process | positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway |
GO_0009986 | Cellular component | cell surface |
GO_0010008 | Cellular component | endosome membrane |
GO_0016020 | Cellular component | membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0015293 | Molecular function | symporter activity |
GO_0140360 | Molecular function | cyclic-GMP-AMP transmembrane transporter activity |
GO_0022857 | Molecular function | transmembrane transporter activity |
Gene name | SLC46A2 |
Protein name | Solute carrier family 46 member 2 Solute carrier family 46 member 2 (Thymic stromal cotransporter homolog) |
Synonyms | TSCOT |
Description | FUNCTION: Proton-coupled transporter that delivers pathogen-associated or danger-associated molecular patterns to cytosolic pattern recognition receptors as part of the innate immune response to microbes or tissue injury . Has selectivity toward muropeptides that contain the amino acid diaminopimelic acid (DAP-type peptidoglycan muropeptides) including Tri-DAP and tracheal toxin (TCT), common in Gram-negative bacteria and Gram-positive bacilli. In the context of immune recognition of skin microbiota, shuttles bacterial muropeptides across the endolysosomal membranes into the cytosol for recognition by NOD1, triggering MYD88-dependent secretion of IL1A and neutrophil recruitment in a pyroptosis-type inflammatory process . To a lesser extent and redundantly, transports muramyl dipeptides derived from most bacterial proteoglycans, eliciting NOD2 receptor activation and downstream inflammatory responses . Postulated to function as a dominant importer of cyclic GMP-AMP dinucleotides (cGAMPs) in monocyte and macrophage cell lineages. Selectively imports cGAMPs derived from pathogenic bacteria such as 3'3'-cGAMP thus providing for differential immune recognition of pathogenic versus commensal bacteria. During tumorigenesis may transport extracellular tumor-derived 2'3'-cGAMP across the plasma membrane of M1-polarized macrophages to activate the anti-tumoral stimulator of interferon genes (STING) pathway . The transport mechanism, its electrogenicity and stoichiometry remain to be elucidated (Probable). . |
Accessions | Q9BY10 S4R3Y2 ENST00000374228.5 ENST00000491462.2 |